Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for
intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic
solution for IVT injection (2 mg) in subjects with untreated active choroidal
neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study
eye.